Recent Updates
Recently added Catalysts

Duragesic

Phase 4

Undisclosed | Small molecule | Other |Johnson & Johnson|Trials Updated: Feb 3, 2025

Duragesic development status

Highest phase Phase 4 (NCT01795898)
Phase scored for JNJPhase 1
Registered trials 24 across 17 sponsors since Sep 2005

Duragesic target and mechanism

ModalitySmall molecule

Also known as Duragesic (Fentanyl Transdermal System [TDS] Small Patches), Fentanyl

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials7
Total Enrollment962

FDA Designations

No designations recorded

Duragesic clinical trials

Duragesic · 7 trials · 10 indications

Phase 3 5Phase 2 1Phase 1 1
NCT01008618A Confirmatory Study of Fentanyl in Participants With Osteoarthritis or Low Back PainChronic Pain
COMPLETED218 Analytics
NCT01008553A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain SyndromePostherpetic Neuralgia
COMPLETED258 Analytics
NCT00788372An Efficacy and Safety Study of Fentanyl in Participants With Chronic PainChronic Pain
COMPLETED142 Analytics
NCT00641667An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer PainPain
COMPLETED66 Analytics
NCT00216684Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and PharmacokineticsPain, Intractable
COMPLETED139 Analytics
PHASE3COMPLETED
A Confirmatory Study of Fentanyl in Participants With Osteoarthritis or Low Back Pain
Chronic PainUnlock trial analytics
PHASE3COMPLETED
A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome
Postherpetic NeuralgiaUnlock trial analytics
PHASE3COMPLETED
An Efficacy and Safety Study of Fentanyl in Participants With Chronic Pain
Chronic PainUnlock trial analytics
PHASE3COMPLETED
An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain
PainUnlock trial analytics
PHASE3COMPLETED
Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics
Pain, IntractableUnlock trial analytics

Study Endpoints

Primary Endpoints

Time From the Initial Day of Application in Double-Blind Period to Withdrawal Because of Insufficient Analgesic Efficacy
Day 1 up to Day 85 (double-blind period) and Day 92 (discontinuation of the study)

Time from start of double-blind (researchers and participants were unaware of the treatment) period to withdrawal because of insufficient analgesic efficacy based on any of the pre-defined discontinuation criteria was noted.

Questionnaire of Opioid Withdrawal Symptoms
Week 52 or endpoint (1 week after last treatment or early discontinuation)

Questionnaire of opioid withdrawal symptoms is a clinician rated 11-item scale that primarily evaluates the physical components of opioid withdrawal and is based on questions and clinical observations. The total score of questionnaire of opioid withdrawal symptoms is the sum of all individual items, with less than (\<) 5 points = no withdrawal, 5 to 12 points = mild withdrawal, 13 to 24 points = moderate withdrawal, 25 to 36 points = moderately severe withdrawal and greater than (\>) 36 points = severe withdrawal.

Dependence Questionnaire (DQ)
Week 52 or end point (early discontinuation)

The DQ is a clinician rated 5-item scale that evaluates dependence on drug and based on questions (Q). Based on participant's answer to Q in questionnaire, Investigator assessed whether drug dependence occurred. It comprises 5 Q which are: continuing drug for reason other than pain, using drug in more dosage than prescribed to have effect other than treatment of pain, have ever used drug with more dosage than prescribed for other purpose, anxiety with the thought of stopping drug for reason other than aggravation of symptoms by stopping this drug and feeling to violate law to get this drug.

Pain Visual Analogue Scale Score
Week 52 or end point (early discontinuation)

Pain visual analog scale was used to assess the amount of pain experienced by the participant throughout the day by marking a slash through the line of a 100 millimeter (mm) scale measuring pain from "no pain (0 mm)" to "worst possible pain (100 mm)".

Number of Participants With Pain Assessed by Categorical Scale for Pain
Week 52 or final evaluation (early discontinuation)

Pain intensity was measured by assessing the average intensity of pain experienced by the participant in daily living throughout the day by 4 grades: no pain at all, mild (slightly painful, but not worried), moderate (painful, but bearable) and severe (painful and unbearable).

Number of Participants With Total Painful Time Per Day
Week 52 or final evaluation (early discontinuation)

The participants assessed total painful time in 1 day by the following 5 grades: less than 4 hours, 4 hours to less than 8 hours, 8 hours to less than 12 hours, 12 hours or more and all day.

Number of Participants With Quality of Sleep
Week 52 or final evaluation (early discontinuation)

The quality of sleep was assessed by participants that how well they have slept from the previous assessment to current assessment time by the following 4 grades: can sleep well, can sleep moderately well, cannot sleep much and cannot sleep at all.

Number of Rescue Treatments
Week 52 or final evaluation (early discontinuation)

Rescue treatment was used for participants with lack of analgesic efficacy, to have relief from breakthrough pain and in cases where withdrawal symptoms occur. The reference one-time rescue dose used was oral morphine 5 milligram (mg) for the investigational product fentanyl one-day transdermal patch 12.5 mcg per hr. The number of rescue treatments per day were reported.

Short-Form 36-Item Health Survey (SF-36) Scores
Week 52 or final evaluation (early discontinuation)

The SF-36 is 36-item form related to 8 health concepts (physical functioning, role physical, role emotional, general health, social functioning, bodily pain, vitality, mental health) and 2 summary scores (physical and mental component summary). Physical functioning, role physical and bodily pain contribute to physical component; role emotional, social functioning and mental health contribute to mental component; and social functioning, vitality, and general health contribute to both. All scores are based on a scale from 0 to 100, with higher scores defining more favorable health state.

Physician's Global Assessment Scale
Week 52 or final evaluation (early discontinuation)

The treating physician assessed the therapeutic efficacy of the treatment by 2 grades: effective and ineffective. Numbers of participants with effective and ineffective therapeutic efficacy with the treatment were reported.

Participants Overall Assessment
Week 52 or final evaluation (early discontinuation)

The participants assessed their satisfaction with therapeutic efficacy by 5 grades: satisfied very much, satisfied, equivocal, dissatisfied and dissatisfied very much. Percentage of participants who were at least satisfied (satisfied, satisfied very much) or at least neither satisfied nor dissatisfied (dissatisfied, dissatisfied very much) were reported.

Brief Pain Inventory-Short Form (BPI-SF) Total Score
Week 52 or final evaluation (early discontinuation)

The BPI-SF is a self-report questionnaire designed to assess the severity and impact of pain on daily functions. It includes pain interference score which is mean value for scores for 9 BPI-SF questions ranging between 0 (does not interfere) to 10 (completely interferes) and pain subscale score which is mean value for scores for BPI-SF questions 3 to 6 ranging between 0 (no pain) to 10 (pain as bad as can imagine). Total BPI-SF score is an average of pain interference score and pain subscale score and ranges from 0 to 10; higher score indicates more pain or pain interference.

Percentage of Participants Achieving Pain Control
Day 10 or early discontinuation (ED)

Pain control was assessed based on change in Visual Analog Scale (VAS) and number of daily rescue doses during 3 days before completion of study drug from 3 days before start of study drug. For VAS score, a difference of less than or equal to +15 millimeter (mm) and for rescue doses, a difference of less than or equal to 1 was considered significant to achieve pain control. Pain Intensity VAS ranged from 0 mm (no pain) to 100 mm (severest pain conceivable) and rescue dose was defined as dose of fast-acting opioid analgesic (except fentanyl preparations) used for lack of analgesic effect.

Patient's global assessments of pain on the completion day of Treatment period 1
Patient's global assessments of pain
Cumulative Adhesion Percentage
Time of patch application up to patch removal (up to 72 hours)

The actual percentages of patch adhesion will be estimated according to the Food and Drug Administration (FDA) 0-4 scoring system. An estimated percentage of adhesion, to a whole integer, will be obtained (FDA 0-4 \[%\] scoring) where 0=greater than or equal to (\>=) 90% adhered (essentially no lift off the skin); 1= \>= 75% to \< 90% adhered (some edges only lifting off the skin); 2 = ≥ 50% to \< 75% adhered (less than half of the patch lifting off the skin); 3 = \> 0% to \< 50% adhered but not detached (more than half of the patch lifting off the skin without falling off); 4 = 0% adhered - patch detached (patch completely off the skin).

Secondary Endpoints

Pain Visual Analog Scale (VAS) Score - Titration Period
Day 12-14 (Screening period) and Day 27-29 (Titration period)
Pain Visual Analog Scale (VAS) Score - Double-Blind Period
Day 27-29 (Titration period) and Day 83-85 (double-blind period)
Number of Participants Evaluated as Per Participant's Overall Assessment - Titration Period
Day 1 and 29 or final evaluation (Titration period)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Fentanyl (Titration period)EXPERIMENTALOne-day adhesive transdermal patch containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2 days, which will be increased by 12.5 mcg/hr at one time based on the medical examination of number of rescue treatments and visual analog scale (VAS) score of the participants. The dose will be increased up to maximum of 50 mcg/hr. The treatment will be continued for 10-29 days and then the eligible participants from this group will be randomly assigned to either of the two groups in the double-blind period.
Fentanyl (Double-blind period)EXPERIMENTALParticipants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to fentanyl group, will be administered one-day adhesive transdermal patch containing fentanyl, applied to chest, abdomen, upper arm and thigh and replaced every day, the dose of which will be same as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will be continued for 12 weeks.
Placebo (Double-blind period)PLACEBO_COMPARATORParticipants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to placebo group, will be administered one-day adhesive transdermal placebo patch indistinguishable from fentanyl in appearance, applied to chest, abdomen, upper arm and thigh and replaced every day. The dose of fentanyl (from titration period) will be gradually decreased to prevent withdrawal symptoms and the dose of the matching placebo will be gradually increased up to same dose as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will continue for 12 weeks.
FentanylEXPERIMENTALFentanyl transdermal patch will be applied once daily up to 4 weeks in Treatment period 1, releasing at the rate of 12.5 microgram per hour (mcg/hr), maintained for 2 days and for another 48 weeks in Treatment period 2. The dose will be increased as per Investigators' discretion in both treatment periods and the maximum applied dose will be 300 mcg/hr. Total duration of treatment is 52 weeks.
Treatment Sequence (ACB) Position (RLR)EXPERIMENTALParticipants will receive treatment A (Duragesic 12.5 microgram per hour \[mcg/h\]) applied to right paraspinal side in period 1, then treatment C (aged JNJ- 35685-AAA-G016 12.5 mcg/h) applied to left paraspinal side in period 2 and then treatment B (New JNJ-35685- AAA-G016 12.5 mcg/h) applied to right paraspinal side in period 3.
Treatment Sequence (BAC) Position (RLR)EXPERIMENTALParticipants will receive treatment B applied to right paraspinal side in period 1, then treatment A applied to left paraspinal side in period 2 and then treatment C applied to right paraspinal side in period 3.
Treatment Sequence (CBA) Position (RLR)EXPERIMENTALParticipants will receive treatment C applied to right paraspinal side in period 1, then treatment B applied to left paraspinal side in period 2 and then treatment A applied to right paraspinal side in period 3.
Treatment Sequence (BCA) Position (RLR)EXPERIMENTALParticipants will receive treatment B applied to right paraspinal side in period 1, then treatment C applied to left paraspinal side in period 2 and then treatment A applied to right paraspinal side in period 3.
Treatment Sequence (CAB) Position (RLR)EXPERIMENTALParticipants will receive treatment C applied to right paraspinal side in period 1, then treatment A applied to left paraspinal side in period 2 and then treatment B applied to right paraspinal side in period 3.
Treatment Sequence (ABC) Position (RLR)EXPERIMENTALParticipants will receive treatment A applied to right paraspinal side in period 1, then treatment B applied to left paraspinal side in period 2 and then treatment C applied to right paraspinal side in period 3.
Treatment Sequence (ACB) Position (LRL)EXPERIMENTALParticipants will receive treatment A applied to left paraspinal side in period 1, then treatment C applied to right paraspinal side in period 2 and then treatment B applied to left paraspinal side in period 3.
Treatment Sequence (BAC) Position (LRL)EXPERIMENTALParticipants will receive treatment B applied to left paraspinal side in period 1, then treatment A applied to right paraspinal side in period 2 and then treatment C applied to left paraspinal side in period 3.
Treatment Sequence (CBA) Position (LRL)EXPERIMENTALParticipants will receive treatment C applied to left paraspinal side in period 1, then treatment B applied to right paraspinal side in period 2 and then treatment A applied to left paraspinal side in period 3.
Treatment Sequence (BCA) Position (LRL)EXPERIMENTALParticipants will receive treatment B applied to left paraspinal side in period 1, then treatment C applied to right paraspinal side in period 2 and then treatment A applied to left paraspinal side in period 3.
Treatment Sequence (CAB) Position (LRL)EXPERIMENTALParticipants will receive treatment C applied to left paraspinal side in period 1, then treatment A applied to right paraspinal side in period 2 and then treatment B applied to left paraspinal side in period 3.
Treatment Sequence (ABC) Position (LRL)EXPERIMENTALParticipants will receive treatment A applied to left paraspinal side in period 1, then treatment B applied to right paraspinal side in period 2 and then treatment C applied to left paraspinal side in period 3.
Treatment Sequence (DFE) Position (RLR)EXPERIMENTALParticipants will receive treatment D (Duragesic 100 mcg/h) applied to right paraspinal side in period 1, then treatment F (aged JNJ-35685-AAA-G021 100 mcg/h) applied to left paraspinal side in period 2 and then treatment E (new JNJ-35685-AAA-G021 100 mcg/h) applied to right paraspinal side in period 3.
Treatment Sequence (EDF) Position (RLR)EXPERIMENTALParticipants will receive treatment E applied to right paraspinal side in period 1, then treatment D applied to left paraspinal side in period 2 and then treatment F applied to right paraspinal side in period 3.
Treatment Sequence (FED) Position (RLR)EXPERIMENTALParticipants will receive treatment F applied to right paraspinal side in period 1, then treatment E applied to left paraspinal side in period 2 and then treatment D applied to right paraspinal side in period 3.
Treatment Sequence (EFD) Position (RLR)EXPERIMENTALParticipants will receive treatment E applied to right paraspinal side in period 1, then treatment F applied to left paraspinal side in period 2 and then treatment D applied to right paraspinal side in period 3.
Treatment Sequence (FDE) Position (RLR)EXPERIMENTALParticipants will receive treatment F applied to right paraspinal side in period 1, then treatment D applied to left paraspinal side in period 2 and then treatment E applied to right paraspinal side in period 3.
Treatment Sequence (DEF) Position (RLR)EXPERIMENTALParticipants will receive treatment D applied to right paraspinal side in period 1, then treatment E applied to left paraspinal side in period 2 and then treatment F applied to right paraspinal side in period 3.
Treatment Sequence (DFE) Position (LRL)EXPERIMENTALParticipants will receive treatment D applied to left paraspinal side in period 1, then treatment F applied to right paraspinal side in period 2 and then treatment E applied to left paraspinal side in period 3.
Treatment Sequence (EDF) Position (LRL)EXPERIMENTALParticipants will receive treatment E applied to left paraspinal side in period 1, then treatment D applied to right paraspinal side in period 2 and then treatment F applied to left paraspinal side in period 3.
Treatment Sequence (FED) Position (LRL)EXPERIMENTALParticipants will receive treatment F applied to left paraspinal side in period 1, then treatment E applied to right paraspinal side in period 2 and then treatment D applied to left paraspinal side in period 3.
Treatment Sequence (EFD) Position (LRL)EXPERIMENTALParticipants will receive treatment E applied to left paraspinal side in period 1, then treatment F applied to right paraspinal side in period 2 and then treatment D applied to left paraspinal side in period 3.
Treatment Sequence (FDE) Position (LRL)EXPERIMENTALParticipants will receive treatment F applied to left paraspinal side in period 1, then treatment D applied to right paraspinal side in period 2 and then treatment E applied to left paraspinal side in period 3.
Treatment Sequence (DEF) Position (LRL)EXPERIMENTALParticipants will receive treatment D applied to left paraspinal side in period 1, then treatment E applied to right paraspinal side in period 2 and then treatment F applied to left paraspinal side in period 3.

Interventions

NameTypeDescription
FentanylDRUGOne-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
PlaceboDRUGPlacebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
Duragesic (Fentanyl Transdermal System [TDS] Small Patches)DRUGDuragesic 12.5 mcg/h (Treatment A) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)DRUGNew JNJ-35685-AAA-G016 12.5 mcg/h (Treatment B) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)DRUGAged JNJ-35685-AAA-G016 12.5 mcg/h (Treatment C) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Duragesic (Fentanyl TDS Large Patches)DRUGDuragesic 100 mcg/h (Treatment D) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours, applied to the paraspinal region of the back for 72 hours.
New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)DRUGNew JNJ-35685-AAA-G021 100 mcg/h (Treatment E) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)DRUGAged JNJ-35685-AAA-G021 100 mcg/h (Treatment F) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Unlock Study Design Details

Eligibility Criteria

Age Range20 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites59

Inclusion Criteria: * Participants whose pain because of osteoarthritis or low back pain is continuing for at least 12 weeks prior to informed consent * Participants who are continuously taking a non-opioid analgesic at the normal highest dose or more for at least 14 consecutive days prior to infor...

Countries:JapanUnited States
Unlock Eligibility Criteria

Frequently asked questions about Duragesic

What is Duragesic?

Duragesic is a fentanyl transdermal system, a patch that delivers the opioid fentanyl through the skin. It is developed by Johnson & Johnson, which trades under the ticker JNJ. The product is also referred to as the Fentanyl Transdermal System (TDS) small patches.

Who makes Duragesic?

Duragesic is made by Johnson & Johnson, ticker JNJ. The company develops the fentanyl transdermal system and has studied new formulations of the patch against the Duragesic fentanyl transdermal patch in clinical research.

What phase is Duragesic in?

Duragesic is listed at Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The completed study enrolled 52 healthy participants and was randomized and controlled, though it was not double blind.

What clinical trials is Duragesic in?

Duragesic has been studied in one completed Phase 1 trial, NCT02608320. That study evaluated adherence of two strengths of newly manufactured and aged samples of a new fentanyl transdermal system formulation compared with the Duragesic fentanyl transdermal patch in healthy participants in the United States.

Is Duragesic the same as the Fentanyl Transdermal System small patches?

Yes. Duragesic is also known as the Fentanyl Transdermal System (TDS) small patches. Both names refer to the same fentanyl transdermal product developed by Johnson & Johnson under ticker JNJ.